跳至主要内容
临床试验/ISRCTN04561582
ISRCTN04561582已完成不适用

TUGENDHAT Study

Olomouc University Hospital (Czech Rebublic)0 个研究点目标入组 120 人开始时间: 2011年8月16日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Bradycardia pacing indication
  • 2. Subject has stable medication (nitrates, diuretics, betablockers) within the last 3 months 3. Echocardiographic exclusion of ventricular (inter-and intra) dyssynchrony
  • 4. Willing and able to comply with the Clinical investigation Plan
  • 5. Signed Informed consent form
  • 6. Aavailability for follow-up visits

排除标准

  • 1. Age less 18 years
  • 2. Indication for biventricular pacing
  • 3. LV EF less than15%
  • 4. Stable NYHA IV
  • 5. Intravenous diuretics, ionotropics medication
  • 6. Enrollment in a concurrent study that may confound the results of this study
  • 7. Post heart transplant or awaiting heart transplantation
  • 8. Renal insufficiency requiring dialiysis
  • 9. Anticipation of poor compliance
  • 10. Pregnancy
  • 11. Life expectancy less than 12 months
  • 12. The inform consent form not signed

研究者

发起方
Olomouc University Hospital (Czech Rebublic)

相似试验

进行中(未招募)
1 期
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
进行中(未招募)
1 期
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placebo
EUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
进行中(未招募)
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861
EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
进行中(未招募)
不适用
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201Coronary Artery DiseaseMedDRA version: 8.1Level: PTClassification code 10011078
EUCTR2005-006029-94-BEEisai Limited720
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943
NL-OMON30044Janssen-Cilag82
Trial on the effect of biventricUlar pacinG in... | 临床试验